(function(){var loadHandler=window['sl_{EC00A760-FAC2-48CD-8603-FA3C7FB92E6B}'];loadHandler&&loadHandler(25, '<div id="spr0_3655a04"><div id="spr1_3655a04" class="kern slide"><img id="img2_3655a04" src="data/img9.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_3655a04" class="kern slide"><img id="img0_3655a04" src="data/img10.png" width="1279.68" height="720" alt="" style="left:0.32px;"/><div id="svg3_3655a04" style="left:1071.779px;top:0px;"><svg width="120" height="51" viewBox="0 0 120 51"><g fill="none"><g><path fill="#ffc000" d="M0,0 H119.167 L118.989,1.767 C113.335,29.398 88.887,50.183 59.584,50.183 C30.281,50.183 5.832,29.398 0.178,1.767 Z" fill-rule="evenodd"/></g></g></svg></div><div id="spr3_3655a04" style="left:88px;top:38.333px;"><div style="width:0px;"><span id="txt0_3655a04" data-width="508.520844" style="left:9.6px;top:24.307px;">Development aspects</span></div></div><div id="spr4_3655a04" style="left:279.362px;top:222.543px;"><img id="img1_3655a04" src="data/img50.png" width="228.438" height="246.191" alt="" style="top:-13.878px;"/></div><div id="spr5_3655a04" style="left:88px;top:191.667px;"><div style="width:0px;"><span id="txt1_3655a04" class="nokern relpos" dir="auto" style="left:9.6px;top:-1.062px;">•</span> <span id="txt2_3655a04" class="relpos" data-width="1040.687500" style="left:22.397px;top:-5.57px;">Trial/Dev characteristics; implications for paediatric onc dev, e.g. larotrectinib in</span></div><div style="width:0px;"><span id="txt3_3655a04" data-width="964.343750" style="left:33.6px;top:25.15px;">EU (to provide further PK data in small children + data on long-term safety</span></div><div style="width:0px;"><span id="txt4_3655a04" data-width="301.421875" style="left:33.6px;top:55.87px;">particularly in children)</span></div><div style="width:0px;"><span id="txt5_3655a04" class="nokern relpos" dir="auto" style="left:9.6px;top:103.662px;">•</span> <span id="txt6_3655a04" class="relpos" data-width="838.687500" style="left:22.397px;top:99.154px;">Current pipeline (emerging molecules and type of ongoing trials)</span></div><div style="width:0px;"><span id="txt7_3655a04" class="nokern relpos" dir="auto" style="left:9.6px;top:147.715px;">•</span> <span id="txt8_3655a04" class="relpos" data-width="283.296875" style="left:22.397px;top:143.207px;">Cases beyond NSCLC?</span></div><div style="width:0px;"><span id="txt9_3655a04" class="nokern relpos" dir="auto" style="left:9.6px;top:191.768px;">•</span> <span id="txt10_3655a04" class="relpos" data-width="976.062500" style="left:22.397px;top:187.26px;">E.g., MSI-H/dMMR cancer studies with the hypothesis that anti PD-1/PD-L1</span></div><div style="width:0px;"><span id="txt11_3655a04" data-width="1043.875000" style="left:33.6px;top:218.75px;">antibodies are effective in the treatment of MSI-H cancers, regardless of tumour</span></div><div style="width:0px;"><span id="txt12_3655a04" data-width="911.593750" style="left:33.6px;top:249.47px;">histology, because MSI-H/dMMR cancer is associated with a high TMB</span></div><div style="width:0px;"><span id="txt13_3655a04" data-width="903.843750" style="left:33.6px;top:280.19px;">(hypermutated phenotype) leading to high neo-antigen expression… .</span></div><div style="width:0px;"><span id="txt14_3655a04" data-width="986.906250" style="left:33.6px;top:310.91px;">Subsequently, the high neo-antigen expression leads to autologous immune</span></div><div style="width:0px;"><span id="txt15_3655a04" data-width="1051.546875" style="left:33.6px;top:341.63px;">recognition of the cancer cells’ immune rec inhibited by PD-1 &gt; blocking the PD-1</span></div><div style="width:0px;"><span id="txt16_3655a04" data-width="977.953125" style="left:33.6px;top:372.35px;">signal pathway on tumour neo-antigen-specific T cells with anti PD-1/PD-L1</span></div><div style="width:0px;"><span id="txt17_3655a04" class="relpos" data-width="792.296875" style="left:33.6px;top:403.66px;">antibodies can reactivate immune responses of said T-cells… </span> <span id="txt18_3655a04" class="relpos" data-width="207.656250" style="left:33.593px;top:403.66px;">Multiple assays.</span></div></div></div></div>', '{"s":[]}');})();